61.17USD-1.75%Mkt Cap: 2.62B USDP/E: —Last update: 2026-05-26
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotil…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.62B USD
Enterprise Value2.43B USD
Revenue (TTM)535.08M USD
Gross Profit420.68M USD
Net Income (TTM)-66.42M USD
Revenue/Share12.54 USD
Last Price61.17 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees370
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)23.18
PEG—
EV/EBITDA-49.60
EV/Revenue4.54
P/S5.10
P/B7.87
EPS (TTM)-1.11
EPS (Forward)2.74
52W Range
38.5148% of range85.25
52W High85.25 USD
52W Low38.51 USD
Profitability
Gross Margin93.20%
Oper. Margin-3.78%
EBITDA Margin-9.16%
Profit Margin-14.72%
ROE-19.34%
ROA-11.81%
Growth
Revenue Growth106.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.45M USD
CapEx (TTM)9.86M USD
FCF Margin-3.97%
FCF Yield-0.81%
Net Debt-300.06M USD
Net Debt/EBITDA6.12
Balance Sheet
Debt/Equity0.21
Current Ratio3.74
Quick Ratio3.53
Book Value/Sh8.070 USD
Cash/Share9.035 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)94.11 USD
Target Range88.00 USD – 100.00 USD
# Analysts9
Ownership
Shares Out.43.02M
Float32.12M
Insiders3.07%
Institutions109.16%
Short Interest
Short Ratio9.4d
Short % Float11.57%
Short % Out.11.20%
Shares Short4.82M
Short (prev mo.)4.58M
Technical
SMA 5065.99 (-7.3%)
SMA 20067.63 (-9.6%)
Beta0.53
S&P 52W Chg28.31%
Avg Vol (30d)676.52K
Avg Vol (10d)825.60K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—